Correction to: Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine (Journal of Pharmacology and Experimental Therapeutics (2017) 361:1 (9-16) DOI: 10.1124/jpet.116.239228);Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 361, Issue 1, 2017, Pages 9-16

  Fukumoto, Kenichi ^a   Toki, Hidetoh ^a   Iijima, Michihiko ^a   Hashihayata, Takashi ^a   Yamaguchi, Jun Ichi ^a   Hashimoto, Kenji ^b   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CORTICOSTERONE; KETAMINE; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CEREBROSPINAL FLUID LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; FORCED SWIM TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; RAT; RODENT; TAIL SUSPENSION TEST; ANIMAL; C57BL MOUSE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; IMMOBILIZATION; INSTITUTE FOR CANCER RESEARCH MOUSE; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB SUSPENSION; KETAMINE; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SWIMMING;

EID: 85018484816     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.239228     Document Type: Erratum

References (34)

1. Alt A, Nisenbaum ES, Bleakman D, and Witkin JM (2006) A role for AMPA receptors in mood disorders. Biochem Pharmacol 71:1273-1288.
2. Bechtholt-Gompf AJ, Smith KL, John CS, Kang HH, Carlezon WA, Jr, Cohen BM, and Ongür D (2011) CD-1 and Balb/cJ mice do not show enduring antidepressantlike effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) 215:689-695.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, and Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
4. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, and Zarate CA, Jr (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605-1611.
5. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678-684.
6. Freedman R (2016) Further Investigation of Ketamine. Am J Psychiatry 173:761-762.
7. Fukumoto K, Iijima M, and Chaki S (2016) The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN. Neuropsychopharmacology 41:1046-1056.
8. Gourley SL and Taylor JR(2009) Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr Protoc Neurosci Chapter 9:Unit 9.32.
9. Hashimoto K (2016a) Ketamine's antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets 20:1389-1392.
10. Hashimoto K (2016b) Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46:2449-2451.
11. Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, and Tsukada H (2016) Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci DOI: 10.1007/s00406-016-0692-7 [published ahead of print].
12. Iijima M, Ito A, Kurosu S, and Chaki S (2010) Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 1359:75-80.
13. Johnson SA, Fournier NM, and Kalynchuk LE (2006) Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav Brain Res 168:280-288.
14. Kohrs R and Durieux ME (1998) Ketamine: teaching an old drug new tricks. Anesth Analg 87:1186-1193.
15. Koike H and Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111-115.
16. Koike H, Iijima M, and Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111.
17. Koike H, Iijima M, and Chaki S (2013) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav 107:20-23.
18. Krystal JH, Sanacora G, and Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133-1141.
19. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, and Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
20. Newport DJ, Schatzberg AF, and Nemeroff CB (2016) Whether ketamine as an antidepressant: panacea or toxin? Depress Anxiety 33:685-688.
21. Paul R, Schaaff N, Padberg F, Möller HJ, and Frodl T (2009) Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 10:241-244.
22. Pazini FL, Cunha MP, Rosa JM, Colla AR, Lieberknecht V, Oliveira Á, and Rodrigues AL (2016) Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. Mol Neurobiol 53: 6818-6834.10.1007/s12035-016-0148-0
23. Popik P, Kos T, Sowa-Kucma M, and Nowak G (2008) Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 198:421-430.
24. Shirayama Y and Hashimoto K (2016) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci DOI: 10.1007/s00406-016-0718-1 [published ahead of print].
25. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, et al. (2016) Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry 80:424-431.
26. Soumier A, Carter RM, Schoenfeld TJ, and Cameron HA (2016) New hippocampal neurons mature rapidly in response to ketamine but are not required for its acute antidepressant effects on neophagia in rats. eNeuro doi: 10.1523/ENEURO.0116-15.2016.
27. Steru L, Chermat R, Thierry B, and Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367-370.
28. The Japanese Association for Laboratory Animal Science (1987) Guidelines for animal experimentation. Exp Anim 36:285-288.
29. Yang C, Han M, Zhang JC, Ren Q, and Hashimoto K (2016a) Loss of parvalbuminimmunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281-283.
30. Yang C, Qu Y, Abe M, Nozawa D, Chaki S, and Hashimoto K (2016b) (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R, 6R)-hydroxynorketamine. Biol Psychiatry DOI: S0006-3223(16)33154-7 [published ahead of print].
31. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, and Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632 10.1038/tp.2015.136.
32. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, et al. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481-486.
33. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, andManji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
34. Zhang JC, Li SX, and Hashimoto K (2014) R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (1)-ketamine. Pharmacol Biochem Behav 116:137-141.